$ESPR News
Last published 1d ago
- 1d agoESPREsperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040GlobeNewswireANN ARBOR, Mich., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Aurobindo Pharma Limited (along with an affiliate). This agreement resolves the patent litigation brought by Esperion against Aurobindo in response to Aurobindo’s Abbreviated New Drug Applications (ANDAs) seeking approval to market g ...
- 1mo agoESPREsperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040GlobeNewswireANN ARBOR, Mich., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Renata Limited (along with an affiliate). This
- 5mo agoESPREsperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026GlobeNewswire– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years – – A Secondary Analysis of CLEAR Outcomes Reports on Patient Factors Associated With 30% or Greater Reduction in LDL-C in Statin
- 6mo agoESPREsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperion's 2017 Inducement
- 6mo agoESPREsperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026GlobeNewswire– Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes – – Pediatric Phase 2 Study Demonstrated
- 6mo agoESPREsperion to be Acquired by ARCHIMEDGlobeNewswireEsperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments Represents total equity value of up to approximately
- 6mo agoESPREsperion to Report First Quarter 2026 Financial Results on May 7GlobeNewswireANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release,
- 7mo agoESPRAthyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis TherapeuticsGlobeNewswireAthyrium Funds purchased a portion of the royalties payable to Esperion on Japan net sales of Otsuka's bempedoic acid products, together with related milestone payments, subject to a cap, for total consideration of $50
- 7mo agoESPREsperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)GlobeNewswire– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued Revenue Growth –
- 7mo agoESPREsperion to Participate in 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireANN ARBOR, Mich., March 31, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will be participating in the webcasted 25th Annual Needham Virtual Healthcare Conference on April 13, 2026,
- 7mo agoESPREsperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026GlobeNewswire– Analysis Demonstrated 22% Reduced Risk of Ischemic Stroke for Patients Taking Bempedoic Acid Compared to Placebo – – Analysis of CLEAR Outcomes Reports Bempedoic Acid Reduced MACE in High-Risk Patients with
- 8mo agoESPREsperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of DyslipidemiaGlobeNewswire– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia – – Bempedoic
- 8mo agoESPREsperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y
- 8mo agoESPRKKREsperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)Business Wire– Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure,
- 8mo agoESPRKKREsperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)GlobeNewswire– Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial
- 8mo agoESPREsperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10GlobeNewswireANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026.
- 8mo agoESPREsperion to Participate in The 2026 Citizens Life Sciences ConferenceGlobeNewswireANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m.
- 8mo agoESPREsperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040GlobeNewswireANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent
- 9mo agoESPREsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireANN ARBOR, Mich., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that on February 10, 2026, the Company granted 11 new employees 40,200 restricted stock units (RSUs) under Esperion's 2017
- 10mo agoESPREsperion Provides Business Update at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – –Total Preliminary* Revenue of $400 to $408 million, a 20% to 23%
- 10mo agoESPRApproval of Nexlizet, Nda #211617 (Labeling)FDA Approved DrugsApproval Date: 01/09/2026; Drug Name: Nexlizet, Nda #211617; Active Ingredients: BEMPEDOIC ACID; EZETIMIBE; Company: Esperion Theraps Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 211617
- 10mo agoESPRApproval of Nexletol, Nda #211616 (Labeling)FDA Approved DrugsApproval Date: 01/09/2026; Drug Name: Nexletol, Nda #211616; Active Ingredients: BEMPEDOIC ACID; Company: Esperion Theraps Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 211616
- 10mo agoESPREsperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireANN ARBOR, Mich., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will present at J.P. Morgan's 44th Annual Healthcare Conference on Wednesday, January 14, 2025. The company's
- 10mo agoESPREsperion's Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With DiabetesGlobeNewswire– Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits – ANN ARBOR, Mich., Dec. 19, 2025 (GLOBE NEWSWIRE) --
- 11mo agoESPREsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that on December 4, 2025, the Company granted three new employees (i) non-qualified stock options to purchase an aggregate of
- 11mo agoESPREsperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of HypercholesterolemiaGlobeNewswire– Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ANN ARBOR, Mich., Nov. 21, 2025 (GLOBE
- 11mo agoESPRApproval of Nexlizet, Nda #211617 (Efficacy)FDA Approved DrugsApproval Date: 11/21/2025; Drug Name: Nexlizet, Nda #211617; Active Ingredients: BEMPEDOIC ACID; EZETIMIBE; Company: Esperion Theraps Inc; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 211617
- 11mo agoESPRApproval of Nexletol, Nda #211616 (Efficacy)FDA Approved DrugsApproval Date: 11/21/2025; Drug Name: Nexletol, Nda #211616; Active Ingredients: BEMPEDOIC ACID; Company: Esperion Theraps Inc; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 211616
- 11mo agoESPREsperion to Participate in Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireANN ARBOR, Mich., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025, at 3:30
- 11mo agoESPREsperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular DiseaseGlobeNewswireANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that HLS Therapeutics Inc. (TSX:HLS), the Company's partner in Canada for the development and commercialization of
- 1y agoESPREsperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025GlobeNewswire– Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo – – An Exploratory Analysis of CLEAR Outcomes Reports
- 1y agoESPREsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that on November 4, 2025, the Company granted 23 new employees 77,650 restricted stock units (RSUs) under Esperion's 2017
- 1y agoESPREsperion Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire– Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million – – Q3 2025 U.S. Net Product Revenue Grew 31% Y/Y to $40.7 Million – – Reached Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic
- 1y agoESPREsperion Appoints Industry Veteran John Harlow as Chief Commercial OfficerGlobeNewswire– Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance – ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the
- 1y agoESPREsperion to Participate in Jefferies Global Healthcare Conference - LondonGlobeNewswireANN ARBOR, Mich., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will present at the Jefferies Global Healthcare Conference – London on November 18, 2025, at 8:00 a.m. GMT
- 1y agoESPREsperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.GlobeNewswire– Leading Cardiovascular Physician Experts to Explore Real-World Challenges and Impact on Patient Outcomes – ANN ARBOR, Mich., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will host a
- 1y agoESPREsperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025GlobeNewswireANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA Scientific Sessions 2025 in
- 1y agoESPREsperion to Report Third Quarter 2025 Financial Results on November 6GlobeNewswireANN ARBOR, Mich., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the
- 1y agoESPREsperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing CholangitisGlobeNewswire– Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases – – ESP-2001 Has the
- 1y agoESPREsperion Announces Pricing of Public Offering of Common StockGlobeNewswireANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. ("Esperion") (NASDAQ:ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral,
- 1y agoESPREsperion Announces Proposed Public Offering of Common StockGlobeNewswireANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. ("Esperion") (NASDAQ:ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral,
- 1y agoESPREsperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040GlobeNewswireANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories, Inc. and its affiliate Dr. Reddy's Laboratories
- 1y agoESPREsperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of HypercholesterolemiaGlobeNewswireANN ARBOR, Mich., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company's partner for the development and commercialization of
- 1y agoESPREsperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoESPREsperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of DyslipidaemiasGlobeNewswire– Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence – – Guideline Recognition of ‘Strike Early and Strike Strong' Approach with Early
- 1y agoESPREsperion to Participate in Upcoming September Investor ConferencesGlobeNewswireANN ARBOR, Mich., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will be participating in the following webcasted investor events during the month of September, which can be
- 1y agoESPREsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion's 2017
- 1y agoESPREsperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoESPREsperion Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire– Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached
- 1y agoESPREsperion to Report Second Quarter 2025 Financial Results on August 5GlobeNewswireANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025. Following the